z-logo
open-access-imgOpen Access
Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis
Author(s) -
Andrea Mafficini,
Eliana Amato,
Matteo Fassan,
Michele Simbolo,
Davide Antonello,
Caterina Vicentini,
Maria Scardoni,
Samantha Bersani,
Marisa Gottardi,
Borislav C. Rusev,
Giorgio Malpeli,
Vincenzo Corbo,
Stefano Barbi,
Katarzyna Sikora,
Rita T. Lawlor,
Giampaolo Tortora,
Aldo Scarpa
Publication year - 2014
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0104979
Subject(s) - kras , sanger sequencing , biology , pathology , pancreatic cancer , cancer , ion semiconductor sequencing , digital polymerase chain reaction , cancer research , ampulla of vater , adenocarcinoma , mutation , gene mutation , cold pcr , pancreas , carcinoma , dna sequencing , gene , polymerase chain reaction , medicine , point mutation , genetics , biochemistry
Background Detection of molecular tumor heterogeneity has become of paramount importance with the advent of targeted therapies. Analysis for detection should be comprehensive, timely and based on routinely available tumor samples. Aim To evaluate the diagnostic potential of targeted multigene next-generation sequencing (TM-NGS) in characterizing gastrointestinal cancer molecular heterogeneity. Methods 35 gastrointestinal tract tumors, five of each intestinal type gastric carcinomas, pancreatic ductal adenocarcinomas, pancreatic intraductal papillary mucinous neoplasms, ampulla of Vater carcinomas, hepatocellular carcinomas, cholangiocarcinomas, pancreatic solid pseudopapillary tumors were assessed for mutations in 46 cancer-associated genes, using Ion Torrent semiconductor-based TM-NGS. One ampulla of Vater carcinoma cell line and one hepatic carcinosarcoma served to assess assay sensitivity. TP53 , PIK3CA , KRAS , and BRAF mutations were validated by conventional Sanger sequencing. Results TM-NGS yielded overlapping results on matched fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissues, with a mutation detection limit of 1% for fresh-frozen high molecular weight DNA and 2% for FFPE partially degraded DNA. At least one somatic mutation was observed in all tumors tested; multiple alterations were detected in 20/35 (57%) tumors. Seven cancers displayed significant differences in allelic frequencies for distinct mutations, indicating the presence of intratumor molecular heterogeneity; this was confirmed on selected samples by immunohistochemistry of p53 and Smad4, showing concordance with mutational analysis. Conclusions TM-NGS is able to detect and quantitate multiple gene alterations from limited amounts of DNA, moving one step closer to a next-generation histopathologic diagnosis that integrates morphologic, immunophenotypic, and multigene mutational analysis on routinely processed tissues, essential for personalized cancer therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom